HE4 tumor marker concentration in neoplastic peritoneal effusion and in peritoneal fluid associated with benign gynecological diseases

被引:5
作者
Chudecka-Glaz, Anita [1 ]
Cymbaluk-Ploska, Aneta [1 ]
Menkiszak, Janusz [1 ]
Sompolska-Rzechula, Agnieszka [2 ]
Byra, Elzbieta [3 ]
Rzepka-Gorska, Izabella [1 ]
机构
[1] Pomeranian Med Univ, Dept Gynecol Surg & Gynecol Oncol Adults & Adoles, PL-70111 Szczecin, Poland
[2] West Pomeranian Univ Technol, Dept Math Applicat Econ, PL-71270 Szczecin, Poland
[3] Pomeranian Med Univ, Cent Lab SPSK 2, PL-70111 Szczecin, Poland
关键词
HE4; Tumor markers; Ascites; Ovarian cancer; OVARIAN-CANCER PATIENTS; PROTEIN; 4; HE-4; SERUM HE-4; PROGNOSTIC-FACTOR; ASCITIC FLUID; BIOMARKER; WFDC2; CARCINOMAS; EXPRESSION; TISSUES;
D O I
10.1186/1757-2215-7-22
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
Background: The aim of our study was to evaluate the behaviour of the human epididymis protein 4 (HE4) in the peritoneal fluid encountered in various female genital diseases. Methods: We enrolled 139 patients, 40 with ovarian cancer (group I), 82 with benign diseases (group II), and 17 with other malignant neoplasms (group III). The HE4 tumor marker concentrations were determined in serum, in the peritoneal effusion and ovarian cyst/ tumor fluids, CA125 in the serum only. We compared the groups, examined correlations and determined corresponding ROC curves. We evaluated the relationship between the HE4 marker concentration in the peritoneal effusion in the group I, depending on the selected prognostic parameters. Results: The HE4 median value between the study groups did not differ statistically significantly and were as follows: in group I 3322 pmol/L, in the group II 2150 pmol/L and in the group III 627 pmol/L (p = 0.206376 for the groups I and II, p = 0.05929 for the groups I and III and p = 0.0797 for the groups II and III. In group I there were no differences found in the HE4 concentrations in the peritoneal fluid, depending on the stage, grade, the presence of neoplastic cells and the peritoneal dissemination. Conclusions: The HE4 marker concentrations in the peritoneal fluid are highly irrespective of the pathology observed in the female sexual organ. Therefore, it seems that its determinations in the peritoneal fluid are completely useless in terms of diagnostics. More research is needed on the role of the HE4 marker, especially the place of its formation and possible use in the targeted therapy.
引用
收藏
页数:10
相关论文
共 31 条
[1]   Ovarian tumor marker HE4 is differently expressed during the phases of the menstrual cycle in healthy young women [J].
Anastasi, Emanuela ;
Granato, Teresa ;
Marchei, Giulia Giovanna ;
Viggiani, Valentina ;
Colaprisca, Barbara ;
Comploj, Sara ;
Reale, Maria Gabriella ;
Frati, Luigi ;
Midulla, Cecilia .
TUMOR BIOLOGY, 2010, 31 (05) :411-415
[2]   Can the preoperative HE4 level predict optimal cytoreduction in patients with advanced ovarian carcinoma? [J].
Angioli, Roberto ;
Plotti, Francesco ;
Capriglione, Stella ;
Aloisi, Alessia ;
Montera, Roberto ;
Luvero, Daniela ;
Miranda, Andrea ;
Cafa, Ester Valentina ;
Damiani, Patrizio ;
Benedetti-Panici, Pierluigi .
GYNECOLOGIC ONCOLOGY, 2013, 128 (03) :579-583
[3]   The putative ovarian tumour marker gene HE4 (WFDC2), is expressed in normal tissues and undergoes complex alternative splicing to yield multiple protein isoforms [J].
Bingle, L ;
Singleton, V ;
Bingle, CD .
ONCOGENE, 2002, 21 (17) :2768-2773
[4]   WFDC2 (HE4): A potential role in the innate immunity of the oral cavity and respiratory tract and the development of adenocarcinomas of the lung [J].
Bingle, Lynne ;
Cross, Simon S. ;
High, Alec S. ;
Wallace, William A. ;
Rassl, Doris ;
Yuan, Guanglu ;
Hellstrom, Ingegerd ;
Campos, Michael A. ;
Bingle, Colin D. .
RESPIRATORY RESEARCH, 2006, 7 (1)
[5]   Preoperative HE4 expression in plasma predicts surgical outcome in primary ovarian cancer patients Results from the OVCAD study [J].
Braicu, E. I. ;
Fotopoulou, C. ;
Van Gorp, T. ;
Richter, R. ;
Chekerov, R. ;
Hall, C. ;
Butz, H. ;
Castillo-Tong, D. Cacsire ;
Mahner, S. ;
Zeillinger, R. ;
Concin, N. ;
Vergote, I. ;
Sehouli, J. .
GYNECOLOGIC ONCOLOGY, 2013, 128 (02) :245-251
[6]  
Chudecka-Glaz A, 2008, EUR J GYNAECOL ONCOL, V29, P37
[7]  
Chudecka-Glaz A, 2012, EUR J GYNAECOL ONCOL, V33, P382
[8]  
Chudecka-Glaz A, 2013, J MOL BIOMARK DIAGN, DOI [10.4172/2155-9929.S4-003, DOI 10.4172/2155-9929.S4-003]
[9]   A phase I-II preoperative biomarker trial of fenretinide in ascitic ovarian cancer [J].
Colombo, Nicoletta ;
Formelli, Franca ;
Cantu, Maria Grazia ;
Parma, Gabriella ;
Gasco, Milena ;
Argusti, Alessandra ;
Santinelli, Alfredo ;
Montironi, Rodolfo ;
Cavadini, Elena ;
Baglietto, Laura ;
Guerrieri-Gonzaga, Aliana ;
Viale, Giuseppe ;
Decensi, Andrea .
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2006, 15 (10) :1914-1919
[10]   Malignant effusions: From diagnosis to biology [J].
Davidson, B .
DIAGNOSTIC CYTOPATHOLOGY, 2004, 31 (04) :246-254